Cadila Healthcare Limited has entered into a definitive agreement with Shilpa Medicare Limited, a contract manufacturing organization to produce mutually agreeable doses of ZyCoV-D. The company also entered into an agreement with Enzychem Lifesciences of Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
545.5 INR | +2.86% | +2.05% | +65.10% |
Apr. 18 | Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US | MT |
Apr. 17 | Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,880 KRW | +0.70% | +6.88% | 116M | ||
947.4 INR | -0.40% | +2.74% | 11.43B | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+65.10% | 568M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- SHILPAMED Stock
- News Shilpa Medicare Limited
- Cadila Healthcare Limited Entered into A Definitive Agreement with Shilpa Medicare Limited and Enzychem Lifesciences